Literature DB >> 11494028

Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.

N Matsutani1, H Yokozaki, E Tahara, H Tahara, H Kuniyasu, K Haruma, K Chayama, W Yasui, E Tahara.   

Abstract

Telomeric repeat binding factor 1 (TRF1) and 2 (TRF2) may play key roles in the maintenance of telomere function. TRF1 negatively regulates telomere elongation, while TRF2 protects the chromosome ends by inhibiting end-to-end fusions. We examined the expression of TRF1 and TRF2 in 20 gastric carcinomas by reverse transcription polymerase chain reaction and then analyzed the relation with telomerase activity and other telomerase components such as human telomerase reverse transcriptase (TERT), human telomerase RNA component (hTR), human telomerase-associated protein (TEP1) and TRF1-interacting, ankyrin-related ADP-ribose polymerase (tankyrase) as well as TRF1-interacting nuclear protein 2 (TIN2). Of 20 gastric carcinomas examined, 10 (50%) and 12 (60%) expressed TRF1 and TRF2 at higher levels than did non-neoplastic mucosa, respectively. No obvious correlation was observed between TRF1 expression and telomerase activity or expression of TERT, hTR and TEP1. Carcinomas with high TRF1 expression expressed significantly higher levels of tankyrase and TIN2 than did those with low TRF2 expression (p<0.05). The telomerase activities and the levels of TERT, hTR and TEP1 showed tendency to be lower in tumors expressing TRF1 at low levels, although it was not significant. On the other hand, carcinomas with short telomere length (shorter than 2 Kbp) expressed significantly stronger telomerase activities and higher TRF1 expression (p<0.05) and tended to express TRF2 and TIN2 at higher levels than those with long telomere length. The results suggest that gastric carcinomas with short telomeres need high levels of telomerase activity and large quantity of TRFs and TIN2, whereas those with long telomeres do not require high levels of telomerase activity and telomere associated proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494028

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  24 in total

1.  Expression of tankyrase 1 in gastric cancer and its correlation with telomerase activity.

Authors:  Jinbo Gao; Jinghui Zhang; Yaoping Long; Yuan Tian; Xiaoming Lu
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

2.  Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis.

Authors:  Raquel Blanco; Purificación Muñoz; Juana M Flores; Peter Klatt; María A Blasco
Journal:  Genes Dev       Date:  2007-01-15       Impact factor: 11.361

Review 3.  Telomeres: protecting chromosomes against genome instability.

Authors:  Roderick J O'Sullivan; Jan Karlseder
Journal:  Nat Rev Mol Cell Biol       Date:  2010-02-03       Impact factor: 94.444

4.  Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells.

Authors:  Masahiro Kato; Masahiro Nakayama; Minako Agata; Kenichi Yoshida
Journal:  Tumour Biol       Date:  2012-12-18

5.  TRF1 controls telomere length and mitotic fidelity in epithelial homeostasis.

Authors:  Purificacion Muñoz; Raquel Blanco; Guillermo de Carcer; Stefan Schoeftner; Roberta Benetti; Juana M Flores; Marcos Malumbres; Maria A Blasco
Journal:  Mol Cell Biol       Date:  2009-01-05       Impact factor: 4.272

Review 6.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

7.  Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

Authors:  María García-Beccaria; Paula Martínez; Marinela Méndez-Pertuz; Sonia Martínez; Carmen Blanco-Aparicio; Marta Cañamero; Francisca Mulero; Chiara Ambrogio; Juana M Flores; Diego Megias; Mariano Barbacid; Joaquín Pastor; Maria A Blasco
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

8.  Moderate expression of TRF2 in the hematopoietic system increases development of large cell blastic T-cell lymphomas.

Authors:  Sebastian Begemann; Francesco Galimi; Jan Karlseder
Journal:  Aging (Albany NY)       Date:  2009-01       Impact factor: 5.682

9.  Stem cell expansion during carcinogenesis in stem cell-depleted conditional telomeric repeat factor 2 null mutant mice.

Authors:  B Bojovic; H-Y Ho; J Wu; D L Crowe
Journal:  Oncogene       Date:  2012-11-26       Impact factor: 9.867

Review 10.  Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumor‑promoting factors (Review).

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Oncol Rep       Date:  2021-07-19       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.